1. 164: PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC). (January 2017) Authors: Kordbacheh, T.; Chan, C.; Bossons, A.; Franks, K.; McDonald, F.; Forster, M.; Mendes, R.; Quezada, S.; Dovedi, S.; Ralph, C.; Popat, S.; Harrington, K.; Melcher, A.; Popple, A.; Illidge, T.; Faivre-Finn, C. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 168: PD-RAD: A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC). (January 2017) Authors: Kordbacheh, T.; Chan, C.; Faivre-Finn, C.; Franks, K.; McDonald, F.; Forster, M.; Mendes, R.; Quezada, S.; Dovedi, S.; Ralph, C.; Popat, S.; Harrington, K.; Melcher, A.; Popple, A.; Illidge, T. Journal: Lung cancer Issue: Volume 103(2017)Supplement 1 Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model. (July 2016) Authors: Cheadle, E.; Lipowska-Bhalla, G.; Fagnano, E.; Klein, C.; Dovedi, S.; Honeychurch, J.; Illidge, T. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: Have We Got the Balance Right?. Issue 8 (August 2015) Authors: Illidge, T. Journal: Clinical oncology Issue: Volume 27:Issue 8(2015) Page Start: 454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in France, Germany Italy, Spain and the United Kingdom. (2019) Authors: Illidge, T.; Bagot, M.; Waser, N.; He, M.; Li, T.; Sambrook, R.; Zomas, A.; Trinchese, F.; Gavini, F.; Little, M.; Ortiz, P.; Pimpinelli, N.; Dalal, M.; Assaf, C. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?. Issue 4 (April 2017) Authors: Marshall, R.; Popple, A.; Kordbacheh, T.; Honeychurch, J.; Faivre-Finn, C.; Illidge, T. Journal: Clinical oncology Issue: Volume 29:Issue 4(2017) Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. LONG TERM FOLLOW‐UP OF FoRT: A PHASE 3 MULTI‐CENTER PROSPECTIVE RANDOMIZED TRIAL OF RADIATION THERAPY FOR FOLLICULAR AND MARGINAL ZONE LYMPHOMA. (12th June 2019) Authors: Hoskin, P.; Kirkwood, A.; Popova, B.; Schofield, O.; Brammer, C.; Robinson, M.; Brunt, M.; Krishnaswamy, M.; Illidge, T.; Gallop‐Evans, E.; Syndikus, I.; Clifton‐Hadley, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS. (June 2017) Authors: Kolstad, A.; Madsbu, U.; Beasley, M.; Bayne, M.; Illidge, T.; O'Rourke, N.; Lagerlöf, I.; Hájek, R.; Jurczak, W.; Willenbacher, E.; Blakkisrud, J.; Muftuler Løndalen, A.; Rojkjaer, L.; Baylor Curtis, L.; Bloma, M.; Turner, S.; Bolstad, N.; Spetalen, S.; Erlanson, M.; Nygaard, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Modeling the immunological response to clinically relevant radiotherapy in a murine prostate tumour model. (July 2016) Authors: Mukherjee, D.; Ani, E.; Honeychurch, J.; Illidge, T. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT. (23rd June 2022) Authors: Illidge, T.; Beasley, M.; Codina, J. G.; Cavallo, F.; Pascal, V.; Wills, V. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1052 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗